leteprinim | 138117-50-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: leteprinim
• 英文别名: 4-[[3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropanoyl]amino]benzoic acid；4-[[3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropyl-] amino] benzoic acid；neotrofin；AIT-082；N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide；Leteprinim；4-[3-(6-oxo-1H-purin-9-yl)propanoylamino]benzoic acid
• CAS: 138117-50-7
• 化学式: C₁₅H₁₃N₅O₄
• 分子量: 327.299
• InChiKey: JMPOIZCOJJMTHI-UHFFFAOYSA-N

物化性质

• 熔点：
  319-321°.
• 沸点：
  825.1±55.0 °C(Predicted)
• 密度：
  1.57±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  126
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  leteprinim 以53的产率得到AIT-082
  参考文献：
  名称：

  [EN] MULTI-FUNCTIONAL PHARMACEUTICAL COMPOUNDS AND METHODS OF USE

  摘要：

  介绍了一种新型多功能药物化合物，其包含至少两个生物活性化学结构基团，由至少一个化学桥接基团连接。所选择的化学基团具有特定的生物活性，包括免疫活性、神经活性、心血管活性和抗微生物活性。这些多功能药物化合物表现出独特的剂量依赖性、协同作用的生物特性，特别适用于治疗相互关联的生理系统。

  公开号：

  WO1991014434A1
• 作为产物：
  描述：

  3-(6-aminopurine-9-yl)-propionic acid ethyl ester 在 氯化亚砜 、 水 、 potassium carbonate 、 溶剂黄146 、 sodium hydroxide 、 sodium nitrite 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 49.0h， 生成 leteprinim
  参考文献：
  名称：

  A New Method for Synthesis and Angiogenic Evaluation of Leteprinim Potassium and Its Novel Analogs

  摘要：

  We developed a novel pathway for the successful synthesis of leteprinim potassium 1, which is one of the candidate substances for treating Alzheimer's disease, and subsequently synthesized 4 types of corresponding novel derivatives 2-5 that have hypoxanthine or 2-chloro-6-aminopurine as the nucleobase. We then determined the angiogenic activity of these compounds by using human umbilical vein endothelial cells. Compounds 1-4 showed no angiogenic potencies judging from statistical analysis, student's t-test.

  DOI：

  10.3987/com-13-12824

文献信息

• [EN] SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF<br/>[FR] COMPOSÉ DE PIPÉRIDINE SUBSTITUÉE ET SON UTILISATION
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2017135306A1

  公开（公告）日：2017-08-10

  Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

  提供的是一种替代哌啶化合物，具有促进俐克脑肽2型受体激动剂活性。公式（I）所代表的化合物：其中每个符号如描述中所述，或其盐具有促进俐克脑肽2型受体激动剂活性，并且可用作嗜睡症的预防或治疗药物。
• Nitrogen-containing tricyclic compounds
  申请人：Yamada Rintaro

  公开号：US20060247266A1

  公开（公告）日：2006-11-02

  A novel compound represented by the following formula (1) or a salt thereof [wherein R 1 , R 5 , R 6 , R 7 , and R 8 represent hydrogen atom, a halogen atom, hydroxyl group, an alkyl group, an alkenyl group and the like; X 1 . . . X 2 represents —CH(R 2 )—CH(R 3 )—, —CH(R 2 )—CH(R 3 )—CH(R 4 )—, —C(R 2 )═C(R 3 )—, or —C(R 2 )═C(R 3 )—CH(R 4 )—(R 2 , R 3 , and R 4 represent hydrogen atom, or an alkyl group); A 1 , A 11 , A 2 , and A 21 represent hydrogen atom, or an alkyl group; Y represents —CH(A 3 )-, —CH(A 3 )-C(A 4 )(A 41 )-, —CH(A 3 )-C(A 4 )(A 41 )-C(A 5 )(A 51 )-, or a single bond (A 3 , A 4 , A 41 , A 5 , and A 51 represent hydrogen atom, or an alkyl group), and Z represents hydroxyl group, or —N(A 6 )(A 61 )(A 6 represents hydrogen atom, or an alkyl group, and A 61 represents hydrogen atom, an alkyl group, a substituted alkyl group and the like)], having an action of potently inhibiting phosphorylation of myosin regulatory light chain.

  以下式（1）表示的新化合物或其盐[其中R1、R5、R6、R7和R8代表氢原子、卤素原子、羟基、烷基、烯基等；X1...X2代表—CH(R2)—CH(R3)—、—CH(R2)—CH(R3)—CH(R4)—、—C(R2)=C(R3)—或—C(R2)=C(R3)—CH(R4)—(R2、R3和R4代表氢原子或烷基)；A1、A11、A2和A21代表氢原子或烷基；Y代表—CH(A3)-、—CH(A3)-C(A4)(A41)-、—CH(A3)-C(A4)(A41)-C(A5)(A51)-或单一键（A3、A4、A41、A5和A51代表氢原子或烷基），Z代表羟基或—N(A6)(A61)(A6代表氢原子或烷基，A61代表氢原子、烷基、取代烷基等)]具有强烈抑制肌球蛋白调节轻链磷酸化的作用。
• HETEROCYCLIC COMPOUND AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20210198240A1

  公开（公告）日：2021-07-01

  The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

  本发明提供了一种具有orexin类型2受体激动剂活性的杂环化合物。 表示为公式(I)的化合物： 其中每个符号如说明书中所述，或其盐具有orexin类型2受体激动剂活性，并且可用作预防或治疗发作性嗜睡症的药剂。
• [EN] RADIOLABELED COMPOUNDS<br/>[FR] COMPOSÉS RADIOMARQUÉS
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2015190613A1

  公开（公告）日：2015-12-17

  The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of CH24H in mammals. The compound of the present invention is represented by the formula (I): wherein each symbol is as defined in the specification.

  本发明提供了用于哺乳动物中CH24H的定量成像的放射性示踪剂有用的放射性标记化合物。本发明的化合物由公式(I)表示：其中每个符号如说明书中所定义。
• GSK-3BETA INHIBITOR
  申请人：Kori Masakuni

  公开号：US20110039893A1

  公开（公告）日：2011-02-17

  For the purpose of providing a GSK-3β inhibitor containing a 2-aminopyridine compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (IA): wherein each symbol is as defined in the specification. or a salt thereof or a prodrug thereof.

  为了提供一种含有2-氨基吡啶化合物或其盐或其前药的GSK-3β抑制剂，用作GSK-3β相关病理或疾病的预防或治疗剂，本发明提供了一种含有由下式（IA）表示的化合物的GSK-3β抑制剂： 其中每个符号如规范中定义。 或其盐或其前药。